Sarepta Therapeutics, Inc. (SRPT)
18.84
+0.72
(+4.00%)
USD |
NASDAQ |
Feb 24, 16:00
18.84
0.00 (0.00%)
After-Hours: 16:08
Sarepta Therapeutics Research and Development Expense (Quarterly) : 218.89M for Sept. 30, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 171.32M |
| Merck & Co., Inc. | 3.992B |
| Pfizer Inc. | 3.206B |
| REGENXBIO, Inc. | 52.22M |
| Keros Therapeutics, Inc. | 19.52M |